Pre- Vs. Postoperative Thromboprophylaxis in Pancreatic Surgery

PHASE4RecruitingINTERVENTIONAL
Enrollment

800

Participants

Timeline

Start Date

August 17, 2022

Primary Completion Date

August 31, 2026

Study Completion Date

September 30, 2026

Conditions
Pancreas CancerPancreas NeoplasmSurgeryThrombosisBleeding
Interventions
DRUG

enoxaparin/tinzaparin/dalteparin

Patients randomized to the preoperative thromboprophylaxis will have their thromboprophylaxis initiated approximately 2-14 hours prior to the planned pancreatic surgery skin incision (depending on the center's current practice and logistics). Thromboprophylaxis can be initiated using enoxaparin (20 - 40 mg), tinzaparin (2500 - 4500 IU), or dalteparin (2500 - 5000 IU), with the dose based on patient's renal function according to the local standard of care. A center may reduce the dose 25-50% if the dose is given very close to the skin incision (i.e. at the morning of the operation instead of the evening before the operation).

Trial Locations (5)

Unknown

RECRUITING

Sunnybrook Health Sciences Centre, Toronto

RECRUITING

Helsinki University Hospital, Helsinki

RECRUITING

Oulu University Hospital, Oulu

RECRUITING

Tampere University Hospital, Tampere

RECRUITING

Oslo University Hospital, Oslo

All Listed Sponsors
lead

Helsinki University Central Hospital

OTHER